Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Dose-Escalation, Placebo-Controlled Study of INCB054707 in Hidradenitis Suppurativa
2018-000827-15Phase 2Completed
- Sponsor
- Incyte
- Start
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in hidradenitis suppurativa (HS) comparing INCB054707 with Placebo (2 arms). Primary endpoint: Safety and tolerability of INCB054707. Started Sep 2018; status: completed.
02
Drugs
povorcitinib
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on 2018-000827-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000827-15.